Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Metabolic activity on [18f]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression might predict clinical outcomes in patients with limited disease small-cell lung cancer who receive concurrent chemoradiation.

Lee J, Kim JO, Jung CK, Kim YS, Yoo IeR, Choi WH, Jeon EK, Hong SH, Chun SH, Kim SJ, Kim YK, Kang JH.

Clin Lung Cancer. 2014 Mar;15(2):e13-21. doi: 10.1016/j.cllc.2013.09.005. Epub 2013 Nov 14.

PMID:
24368212
2.

18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours.

Toba H, Kondo K, Sadohara Y, Otsuka H, Morimoto M, Kajiura K, Nakagawa Y, Yoshida M, Kawakami Y, Takizawa H, Kenzaki K, Sakiyama S, Bando Y, Tangoku A.

Eur J Cardiothorac Surg. 2013 Aug;44(2):e105-12. doi: 10.1093/ejcts/ezt263. Epub 2013 May 14.

PMID:
23674658
3.

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A.

J Clin Oncol. 2013 Oct 20;31(30):3823-30. doi: 10.1200/JCO.2012.47.5947. Epub 2013 Sep 16.

4.

Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.

Lee GW, Go SI, Cho YJ, Jeong YY, Kim HC, Duk Lee J, Hwang YS, Ko GH, Lee JH, Kim DC, Yang JW, Oh S, Lee JS.

J Thorac Oncol. 2012 Mar;7(3):528-34. doi: 10.1097/JTO.0b013e3182417830.

5.

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.

Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ.

Lung Cancer. 2002 Feb;35(2):179-87.

PMID:
11804691
6.

Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.

Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY.

AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.

PMID:
26295651
7.

Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.

Winther-Larsen A, Hoffmann L, Moeller DS, Khalil AA, Knap MM.

Acta Oncol. 2015;54(9):1574-81. doi: 10.3109/0284186X.2015.1062135. Epub 2015 Jul 23.

PMID:
26203924
8.

Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.

Everitt SJ, Ball DL, Hicks RJ, Callahan J, Plumridge N, Collins M, Herschtal A, Binns D, Kron T, Schneider M, MacManus M.

J Nucl Med. 2014 Jul;55(7):1069-74. doi: 10.2967/jnumed.113.131631. Epub 2014 May 15.

9.

Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.

Inal A, Kucukoner M, Kaplan MA, Urakci Z, Nas N, Guven M, Dostbil Z, Altindag S, Isikdogan A.

Rev Port Pneumol. 2013 Nov-Dec;19(6):260-5. doi: 10.1016/j.rppneu.2013.03.007. Epub 2013 Aug 28.

10.

Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer.

Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT.

Cancer Imaging. 2014 Apr 22;14:2. doi: 10.1186/1470-7330-14-2.

11.

Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.

Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J.

Lung Cancer. 2011 Sep;73(3):332-7. doi: 10.1016/j.lungcan.2011.01.007. Epub 2011 Feb 2.

PMID:
21292341
12.

Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.

Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.

Acta Oncol. 2012 May;51(5):636-44. doi: 10.3109/0284186X.2011.643822. Epub 2012 Jan 2.

PMID:
22208782
13.

SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma.

Miyawaki A, Ikeda R, Hijioka H, Ishida T, Ushiyama M, Nozoe E, Nakamura N.

Oncol Rep. 2010 May;23(5):1205-12.

PMID:
20372831
14.

Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.

Sahiner I, Atasever T, Akdemir UO, Ozturk C, Memis L.

Rev Esp Med Nucl Imagen Mol. 2013 Nov-Dec;32(6):357-63. doi: 10.1016/j.remn.2013.03.008. Epub 2013 Jun 6.

15.

Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.

Furukawa T, Miyata Y, Kushitani K, Mimae T, Tsutani Y, Takeshima Y, Okada M.

Jpn J Clin Oncol. 2015 Dec;45(12):1154-61. doi: 10.1093/jjco/hyv138. Epub 2015 Sep 18.

PMID:
26386467
16.

Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.

Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M.

Clin Cancer Res. 2006 Jan 1;12(1):97-106.

17.

Prognostic impact of clinicopathological features and expression of biomarkers related to (18)F-FDG uptake in esophageal cancer.

Schreurs LM, Smit JK, Pavlov K, Pultrum BB, Pruim J, Groen H, Hollema H, Plukker JT.

Ann Surg Oncol. 2014 Nov;21(12):3751-7. doi: 10.1245/s10434-014-3848-6. Epub 2014 Jun 18.

PMID:
24939624
18.

Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.

Liao S, Penney BC, Zhang H, Suzuki K, Pu Y.

Acad Radiol. 2012 Jan;19(1):69-77. doi: 10.1016/j.acra.2011.08.020.

PMID:
22142679
19.

Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.

Abd El-Hafez YG, Moustafa HM, Khalil HF, Liao CT, Yen TC.

Oral Oncol. 2013 Mar;49(3):261-8. doi: 10.1016/j.oraloncology.2012.09.005. Epub 2012 Oct 1.

PMID:
23036774
20.

Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.

Onal C, Reyhan M, Parlak C, Guler OC, Oymak E.

Int J Gynecol Cancer. 2013 Jul;23(6):1104-10. doi: 10.1097/IGC.0b013e3182989483.

PMID:
23792605

Supplemental Content

Support Center